
Early use of the radiopharmaceutical Lutetium-177-PSMA-617 in metastatic prostate cancer improves patients’ daily routine, argue CEPID CancerThera researchers in editorial commentary
Prostate cancer is one of the leading causes of male mortality worldwide, becoming a major clinical challenge when it reaches














